Evoking neuronal activity to improve the lives of Alzheimer’s patients
![cognito vr headset](https://cdn.prod.website-files.com/656e26ef10850ea6428fe577/659da05769cfa6d776284098_230505_GS-V1_6A%203%20(1).webp)
Cognito's headset design concept
We are leading a novel category of disease-modifying therapy in Alzheimer’s disease
Developed with a novel mechanism of action
Research shows that Alzheimer's patients have abnormal neuronal activity in the brain. We're advancing a new way of treating Alzheimer's disease by targeting this abnormal activity.
Promising results from our Phase 2 study
In our Phase 2 OVERTURE trial, significant slowing of disease progression was observed among treated patients through the preservation of cognition, daily function, and whole brain volume. No serious treatment-limiting adverse events were reported.
Designed to fit into patient’s lives
Patients receive this non-invasive treatment from the comfort of their home for one hour each day.
Why do the brain's electrical activities matter?
Neurons communicate through electric signals, creating rhythmic brain activity known as "brain waves." When groups of neurons start firing at the same time, distinct brain waves form at various ranges. One such range is gamma waves, which play an important role in learning and memory. In Alzheimer’s patients, gamma waves are altered, indicating impairment in normal brain function.a
How does our treatment work?
Our novel therapy is designed to evoke gamma wave activity through non-invasive visual and auditory stimulation. In prior clinical studies, it slowed cognitive and functional decline and loss of brain structure among treated Alzheimer's patients.
![](https://cdn.prod.website-files.com/656e26ef10850ea6428fe577/65a1b282d783864da959be62_cognito-3dwave%201%20(4).webp)
![Woman using the cognito VR headset](https://cdn.prod.website-files.com/656e26ef10850ea6428fe577/6682800c0337844145ed78e9_656fb8d6ef5be5b0944534ed_FIREFLIES.webp)
Cognito's headset design concept
![](https://cdn.prod.website-files.com/656e26ef10850ea6428fe577/65a1b41f7dbe94da28b0f02f_cognito-3dwave%203.webp)
![cognito vr headset](https://cdn.prod.website-files.com/656e26ef10850ea6428fe577/6570980332d1d3a3a95d7b60_image%201614.webp)
Cognito's headset design concept
![a woman knitting](https://cdn.prod.website-files.com/656e26ef10850ea6428fe577/6570983ec8ac4905944d7dbd_image%201567.webp)
![a woman drawing](https://cdn.prod.website-files.com/656e26ef10850ea6428fe577/6570a610cc1e428ffa9baec8_image%201566%20(1).webp)
![a man petting his dog](https://cdn.prod.website-files.com/656e26ef10850ea6428fe577/65709882f1ed685507b52ef8_image%201612.webp)
![a woman smiling](https://cdn.prod.website-files.com/656e26ef10850ea6428fe577/657098d7bdb4e9d53ad9d0b8_image%201566.webp)
Our treatment received the FDA Breakthrough Device Designation for the treatment of cognitive and functional symptoms associated with Alzheimer’s disease, and we are expanding our approach to many other indications.
Click to enlarge
It all started with a breakthrough from leading MIT neuroscientists
Press, publications & announcements
August 26, 2024
Cognito Therapeutics Appoints Christian Howell as Chief Executive Officer
July 29, 2024
Cognito Therapeutics Announce OVERTURE I Study Demonstrated Significant Time Savings Using Composite Measures of Function and Cognition
July 8, 2024
Cognito Therapeutics Announces Scientific Presentations at the Alzheimer’s Association International Conference 2024
April 29, 2024
Cognito Therapeutics Announces Presentation at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2024 Meeting
April 15, 2024
Cognito Therapeutics Announces Spectris™ Demonstrates Durable Effects on Activities of Daily Living in the OVERTURE II Study